Quick answer: Retatrutide (LY3437943) has been evaluated in Phase 1b and Phase 2 studies and is now in a broad Phase 3 program. By October 10, 2026, Lilly had announced topline results from several Phase 3 trials, including TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4, and TRANSCEND-T2D-1. These sponsor announcements are not interchangeable with complete peer-reviewed reports, and retatrutide remains investigational.
This guide helps readers assess “retatrutide clinical trial” and “retatrutide trials” information without mixing study stages or overstating outcomes. It summarizes how trial records and papers fit together; it is not medical advice, a treatment recommendation, or a guide to joining a study.
What retatrutide clinical trials have studied
Clinical research on retatrutide, first identified by the development code LY3437943, has progressed through multiple study designs. Early trials assess pharmacology and safety in defined groups; later trials test specific research questions in larger or more targeted populations. A trial’s title may sound broad, but its eligibility criteria and protocol define what the results can support.
Phase 1b research
A randomized Phase 1b study evaluated LY3437943 in adults with type 2 diabetes over a limited treatment period. It assessed safety, tolerability, pharmacokinetics, and selected metabolic endpoints. The results provide early evidence under that protocol; they do not settle every question about long-term outcomes or other populations.
Phase 2 research
A Phase 2 randomized trial published in The New England Journal of Medicine evaluated retatrutide in adults with obesity or overweight and without diabetes. It reported outcomes over its study period, including body-weight change and safety measures. Those findings apply to the enrolled participants, tested study arms, statistical plan, and follow-up described in the paper.
Phase 3 research
Phase 3 programs evaluate retatrutide in larger, defined participant groups and examine protocol-specific outcomes. By October 2026, Lilly had announced topline results from multiple studies: TRIUMPH-1 in adults with obesity or overweight without diabetes; TRIUMPH-2 in participants with type 2 diabetes; TRIUMPH-3 in a cardiovascular-risk population; TRIUMPH-4 in participants with knee osteoarthritis; and TRANSCEND-T2D-1 in type 2 diabetes. For example, Lilly reported a mean 28.3% weight reduction at 80 weeks in the 12 mg TRIUMPH-1 arm. That is a sponsor-reported trial result for a defined study arm, not a head-to-head comparison with another medicine or a prediction for an individual. Check whether full methods and results have appeared in a peer-reviewed paper before treating a news release as a complete evidence record.
How trial phases differ
Trial phase is a shorthand for a development stage, not a quality score or conclusion. A Phase 1 study can provide important pharmacology data, while a Phase 3 study can still be limited by its population, design, comparator, endpoint, or duration. Each study should be read on its own terms.
Questions to ask at each stage
- Early phase: What were the primary safety, tolerability, and pharmacokinetic questions?
- Mid-stage: Which dose groups, comparator, population, and endpoints were prespecified?
- Later stage: What was the primary outcome, how long were participants followed, and were results peer reviewed?
Do not treat the words “Phase 3” or “positive results” as a substitute for the methods and results. Read the actual registry record or article and note whether the information is a protocol, a posted result, a journal paper, or a news release.
How to read trial endpoints and results
An endpoint is a defined outcome used to answer a study question. The primary endpoint is selected in advance as the main measure; secondary and exploratory endpoints address additional questions. A change in one endpoint does not automatically establish changes in every other outcome.
Interpret the comparison, not just the headline number
Check the comparator group, baseline characteristics, participant flow, analysis population, missing-data rules, confidence intervals, and duration. If a study reports a mean change, the average does not describe every participant. The estimate should be read with its uncertainty and the study’s design.
Registry results and journal articles
ClinicalTrials.gov records show the registered study design and may contain results submitted by the responsible party. A peer-reviewed journal article adds a full scientific report, but it still needs critical appraisal. Compare the registry’s planned outcomes with the publication’s reported outcomes and check whether any changes are explained.
What trial registration does—and does not—mean
Registration creates a public record of a study’s identifying information, design, eligibility, interventions, and planned outcomes. It improves transparency and helps readers follow study status. Registration is not an FDA approval decision and does not independently confirm that a result is accurate, clinically meaningful, or applicable outside the study.
Likewise, a press release or conference presentation may report an interim result but provide less detail than a complete article. Label each source accurately and avoid presenting preliminary, sponsor-reported information as a final peer-reviewed conclusion.
How to separate topline announcements from full trial evidence
A topline announcement can help readers track a development program, but it usually cannot replace a full report. Record the source type and date, then look for the prespecified primary endpoint, analysis population, comparator, missing-data approach, confidence intervals, adverse events, and participant flow. Confirm whether a conference abstract or journal paper reports the same study and whether its analyses match the registry protocol.
Do not combine percentages from separate retatrutide trials as though they came from one population. TRIUMPH studies differ in eligibility criteria and clinical context. A result in people with type 2 diabetes, for example, answers a different question from a result in participants without diabetes or a group selected for knee osteoarthritis.
Regulatory status and limits of the evidence
As of October 10, 2026, retatrutide remains investigational and is not FDA-approved. Clinical-trial evidence and regulatory authorization are separate. FDA has also warned about unapproved retatrutide products marketed directly to consumers, including products labeled “for research purposes” or “not for human consumption.” Research on a trial material does not verify the identity or quality of a different product.
This article is for research education only. It does not provide dosing, preparation, injection, treatment, purchasing, or sourcing instructions. Consult the trial paper and official registry for study details, and current FDA resources for regulatory information.
Retatrutide clinical-trial FAQs
What phases of retatrutide research are published?
Peer-reviewed sources include early-phase work and a Phase 2 obesity trial. By October 2026, the sponsor had also announced topline results from several Phase 3 studies. Check each study’s current registry record and whether its full results are peer reviewed.
Does a Phase 3 trial mean retatrutide is approved?
No. A trial phase is part of development. FDA approval is a separate regulatory decision.
Where can I verify a retatrutide trial record?
Search ClinicalTrials.gov by the compound name or development code, then confirm the identifier, sponsor, condition, study status, and outcome fields.
Can one study result predict an individual outcome?
No. Trial averages describe groups studied under a protocol and do not predict an individual’s response.
References
- Urva S, et al. LY3437943 in people with type 2 diabetes: a Phase 1b trial. The Lancet Diabetes & Endocrinology. 2022;10(9):646–656. doi:10.1016/S2213-8587(22)00233-5.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. doi:10.1056/NEJMoa2301972.
- Eli Lilly and Company. TRIUMPH-1 topline Phase 3 results. May 21, 2026. Sponsor announcement; consult the registry and full publication for complete methods and analyses.
- ClinicalTrials.gov. TRIUMPH-1, NCT05929066. Accessed October 10, 2026.
- ClinicalTrials.gov. Retatrutide study records. Accessed October 10, 2026.
- U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Accessed October 10, 2026.
Editorial note: This article summarizes research publications and official trial records. It is not medical advice or an endorsement of any product. Reviewed October 10, 2026.
